Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd is experiencing a notable increase in its equipment utilization rate, which has risen by over 50% since the establishment of its investment arrangement, signaling growing demand for its proprietary Deep TMS technology. Additionally, the company is navigating towards accelerated revenue growth through strategic investments and gaining traction in both pay-per-use models and the neurologist specialist prescriber segment, enhancing its market positioning. The ongoing clinical trials for various psychiatric, neurological, and addiction disorders further underline BrainsWay's commitment to expanding its treatment offerings, contributing to a fundamentally positive outlook on its financial trajectory.

Bears say

BrainsWay Ltd faces significant risks that contribute to a negative outlook on its stock, including a slower-than-expected adoption of its Deep TMS systems, which could hinder revenue generation. Furthermore, the company's failure to expand reimbursement options and market access presents an ongoing challenge that may restrict growth potential. Lastly, the inability to progress in developing Deep TMS for additional indications, coupled with the potential for long-term dilution, adds further uncertainty to its financial stability and future expansion prospects.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.